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ABSTRACT Psoriasis is a multifactorial inflammatory papulosquamous 
disease affecting 0.5% to 2% of the pediatric population. Pediatric pso-
riasis, presenting similar to adult psoriasis, significantly reduces patient 
quality of life, often requiring an individualized treatment approach for 
each patient. Combination and rotational therapy are helpful in reduc-
ing toxicity and maximizing efficacy. Patients with mild and limited dis-
ease severity respond well to topical treatment with steroids or vitamin 
D analogues, unlike moderate and severe psoriasis where sufficient 
remission is rarely achieved. Therefore phototherapy, systemic immu-
nomodulators, or biologic agents are the next line of treatment to be 
considered. There is limited data available on the use and long-term 
safety of biologics in the pediatric population. Biologic agents must 
be administered by experienced dermatologists, only in patients with 
moderate-to-severe plaque psoriasis who are intolerant or refractory 
to other systemic conventional disease-modifying treatment or photo-
therapy, or if those treatments are contraindicated. 
KEY WORDS: pediatric psoriasis; topical treatment; systemic treatment; 
biologic agents
INTRODUCTION
Psoriasis is a chronic and relapsing papulosqua-
mous inflammatory skin disease characterized by sig-
nificantly reduced quality of life and impaired psycho-
social functioning. Therefore, the main goal of treat-
ment is to achieve long-term remission of the disease 
(1,2). Approximately one-third of patients with pso-
riasis develop clinical features in the first two decades 
of life. The congenital form of the disease present at 
birth or in the early neonatal period is extremely rare 
(3). Onset is usually after puberty, with no clear gen-
der predilection (4). Family history is positive in 71% 
of affected children (5). Due to the chronic nature of 
psoriasis, the child and its family must learn to cope 
with the demanding treatment that involves frequent 
applications of topical agents as well as blood tests if 
systemic therapy has been started. The disease has a 
great impact on a child’s well-being and development 
of self-confidence, as psoriasis mostly involves the 
exposed skin. Patients suffer from feelings of shame, 
embarrassment, stigmatization, and social rejection 
(6). In this article, the use of different treatment op-
tions for childhood psoriasis has been reviewed.
CLINICAL PRESENTATION
Plaque psoriasis is the most common form of pedi-
atric psoriasis. The presentation in children resembles 
psoriasis in adults. However, initial lesions are less 
prominent, with mild scaling and induration, and can 
cause diagnostic difficulties (7). It is especially impor-
tant to differentiate psoriasis from atopic dermatitis, 
which is significantly more frequent in the pediatric 
population. In later stages, the clinical presentation is 
dominated by scaly plaques accompanied by itching. 
Psoriasis frequently affects the scalp (Figure 1) in ap-
proximately 58% of patients, extensor surfaces of the 
extremities (Figure 2), trunk (Figure 3), face, and ears. 
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Considering the frequency of different clinical types 
of psoriasis, plaque psoriasis dominates through-
out the childhood, while napkin or diaper psoriasis, 
occurs mostly during the first two years of life (8). 
Analysis of phenotypic variation in comparison with 
age of onset and family history showed that severity 
of skin and nail disease correlates with early onset 
of the disease and positive family history (9). Apart 
from the chronic plaque form, several other patterns 
of psoriasis occur in childhood. Guttate psoriasis is 
characterized by the acute onset of small drop-like 
papules, usually covered with a fine scale. Group A 
streptococcal pharyngitis often precedes the erup-
tion by 1-2 weeks. Streptococcal perianal dermatitis 
has also been linked with the appearance of guttate 
psoriasis (9,10). The disease is usually self-limiting and 
spontaneously resolves within 3-4 months, although 
relapse can occur after 3 to 5 years (4). Intertriginous 
or inverse psoriasis is a relatively rare form of pedi-
atric psoriasis affecting body folds, the genitals, and 
the periumbilical region. Psoriatic nail disease occurs 
in 7-40% of all children with psoriasis, and may be the 
only presenting manifestation of the disease, preced-
ing skin involvement. Signs of nail psoriasis include 
onycholysis, resembling oil drops in the nail bed and 
pitting (Figure 4) (12). Rare forms of pediatric psoria-
sis include localized and generalized pustular psoria-
sis, psoriatic erythroderma, and linear psoriasis. Lin-
ear psoriasis is an uncommon clinical variant of the 
disease with a linear distribution of erythematosqua-
mous lesions along the lines of Blaschko, caused by 
genetic alterations in early embryogenesis (13). 
MANAGEMENT OF PEDIATRIC PSORIASIS
Treatment of psoriasis in pediatric patients is chal-
lenging because of the lack of clinical trials in the 
pediatric population as well as the lack of guidelines. 
Treatment success depends largely on parental in-
volvement and education. Therefore, it is extremely 
important to have a positive approach to the treat-
ment of this chronic disease (14,15). A better under-
standing of the pathogenesis of psoriasis is crucial for 
the effective treatment. Psoriasis is not solely a hyper-
proliferative disease of keratinocytes, but a chronic, 
inflammatory, multisystem disease associated with 
a number of co-morbidities such as cardiovascular 
diseases and metabolic syndrome with hyperlip-
idemia, obesity, hypertension, and diabetes mel-
litus (16). Atherogenic risk, resulting from oxidative 
stress and reduced antioxidant capacity of cells may 
significantly shorten life expectancy (17). Due to its 
Figure 1. Psoriasis of the scalp
Figure 2. Psoriatic lesions on the extremities
Figure 3. Psoriatic lesions on the back of the patient
Madiraca et al. Acta Dermatovenerol Croat
Treatment options for pediatric psoriasis  2016;24(3):175-180
177ACTA DERMATOVENEROLOGICA CROATICA
complex pathogenesis, psoriasis treatment depends 
on disease severity, while the patients’ age should be 
considered at the same time. Treatment should be 
tailored to the individual patient. 
TOPICAL THERAPIES
Limited or mild disease can be managed effec-
tively with topical therapies alone, such as corticoste-
roids, vitamin D analogues, or immunomodulators. 
Calcineurin inhibitors, tacrolimus, and pimecroli-
mus are effective in the treatment of facial and geni-
tal psoriasis (18). Mild to moderate psoriasis of the 
limbs and torso is intermittently treated with topical 
corticosteroids and vitamin D analogues. Topical cor-
ticosteroids have an important role in treatment due 
to antiproliferative, anti-inflammatory, immunosup-
pressive, and vasoconstrictive properties. Lower-po-
tency corticosteroids are especially recommended for 
use on the face, axillary areas, and groin in infants and 
children, whereas mid or higher potency corticoste-
roids can be used on thick psoriatic plaques (19). Side 
effects are not common when topical steroids are 
used sparingly and intermittently. In children, the risk 
of systemic adverse reactions, like hypothalamic-pi-
tuitary-adrenal axis suppression, is higher compared 
with adult patients due to increased surface area-to-
body mass ratio. In order to reduce the side effects, it 
is crucial that appropriate corticosteroid formulation 
is used intermittently on affected skin with manda-
tory supervision during the treatment (20).
PHOTOTHERAPY
Phototherapy is one of the treatment options for 
pediatric patients with moderate to severe psoriasis. 
The most frequently used form is narrow band UVB 
(311 nm) in the treatment of plaque and guttate pso-
riasis. Long-term side effects depend on cumulative 
dosing of UV treatment and include increased risk 
of skin cancer and premature skin aging (21). Pho-
totherapy is time consuming, interferes with school 
attendance and is not the treatment of choice for pa-
tients with phototoxic reactions. 
SYSTEMIC AGENTS
Systemic drug therapy in pediatric patients is 
mostly used for severe disease unresponsive to other 
treatment. Oral medications used for psoriasis treat-
ment include retinoids, methotrexate, and cyclospo-
rine.
Retinoids (e.g. acitretin) are effective treatment 
for erythrodermic and the pustular form of psoria-
sis. However, retinoids bear a high teratogenic risk 
and should be generally avoided or used with con-
comitant oral contraception during and two years 
after stopping the treatment in adolescent girls of 
childbearing potential. Common adverse effects in-
clude dose-dependent cheilitis, pruritus, epistaxis, 
conjunctivitis, and hair loss. Long-term use carries a 
risk of potential growth retardation due to premature 
closure of epiphyses (22,23).
Methotrexate, a folic acid antagonist, is used in 
the treatment of moderate to severe psoriasis and 
psoriatic arthritis in children. It provides a safe and 
effective treatment with regular screening of full 
blood count, liver function tests, and renal function. 
Folic acid supplements reduce side effects such as 
headache, nausea, and gastrointestinal discomfort 
(24,25). 
Cyclosporine, an immunosuppressant and cal-
cineurin inhibitor, can be used in pediatric patients 
with severe plaque psoriasis or as a short-term inter-
vention therapy in relapse of psoriasis (26). The risk of 
nephrotoxicity, immunosuppression, hypertension, 
and mucocutaneous side effects such as hypertricho-
sis and gingival hyperplasia limit its use (27,28).
Use of standard systemic treatment and photo-
therapy, although generally effective, carries the risk 
of cumulative dose side effects, low compliance, and 
even gonadal toxicity, and the satisfactory therapeu-
tic response is not achieved in some patients (29). 
BIOLOGICS
Development of biologics is based on the under-
standing of the complex etiopathogenesis of psoria-
sis. As a response to an unknown trigger, injury, or 
infection, naive immune cells such as macrophages, 
Figure 4. Nail psoriasis
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NK cells, and plasmacytoid dendritic cells produce 
cytokines that stimulate the activation of dendritic 
cells and production of regulatory cytokines such 
as interleukin (IL) 12 and IL-23. IL-12 causes the dif-
ferentiation of Th1 cells that produce tumor necrosis 
factor (TNF) -α and interferon-γ. IL-23 stimulates the 
expansion of Th17 cells secreting IL17 A/F and Th22 
cells secreting IL-22. Interleukins 17 A/F and IL-22 are 
effector cytokines, responsible for the activation and 
proliferation of keratinocytes. Keratinocytes attract 
inflammatory cells via cytokines and chemokines and 
start the inflammatory cycle characteristic for psoria-
sis (30-32). Biologic agents target specific parts of the 
immune system, inhibit T cell activation or migration 
in the skin, and block cytokines important for the de-
velopment of psoriatic lesions. They represent a new 
therapeutic option for treating moderate-to-severe 
plaque psoriasis unresponsive to systemic therapy 
(33). 
Tumor necrosis factor alpha inhibitors that have 
been used in the treatment of pediatric psoriasis in-
clude infliximab, etanercept, and adalimumab. 
Infliximab is a chimeric monoclonal antibody 
against TNF-alpha that has been FDA-approved for 
the treatment of pediatric Crohn’s disease (children 
≥6 years) since 2006. There are sporadic case reports 
on the treatment of pediatric psoriasis. Due to its rap-
id onset of action and its high efficacy, infliximab can 
be used for generalized pustular or erythrodermic 
psoriasis (34,35). 
Etanercept, a TNF receptor fusion protein, was 
long considered the drug of choice for the treatment 
of juvenile psoriasis due to good efficiency and ex-
cellent tolerability and safety profile (36). The Euro-
pean Medicines Agency (EMA) approved etanercept 
in 2009 for the treatment of chronic severe plaque 
psoriasis in pediatric patients (children ≥6 years) who 
are poorly controlled by or are intolerant to other sys-
temic therapies or phototherapy (37,38).
Adalimumab is a recombinant human monoclo-
nal antibody specific to TNF-alpha. It is approved for 
the treatment of chronic severe plaque psoriasis in 
children ≥4 years and adolescents with inadequate 
treatment response to other local therapies or photo-
therapy. Following the results of a multicentre, dou-
ble-blind, phase 3 clinical trial evaluating the safety 
and efficacy of adalimumab 0.8 mg/kg and 0.4 mg/kg 
every other week compared with methotrexate in 
114 patients, aged 4-18 years, adalimumab was ap-
proved for treatment of severe chronic plaque psoria-
sis in children (39).
Biologics are generally safe and well tolerated. 
The most common adverse effect seen with the use 
of anti-TNF agents are injection-site reactions. Long-
term use of anti-TNF agents may increase the risk of 
malignancy, especially lymphomas (40). TNF inhibi-
tors are associated with an increased risk of all types of 
infections, including tuberculosis and invasive fungal 
and opportunistic infections. Adverse events in chil-
dren and teenagers are generally similar in frequency 
and type as those seen in adult patients (41). Patients 
receiving TNF-alpha inhibitor treatment should be 
monitored for infections and should be educated 
about how to recognize signs of infection early and 
avoid fatal complications. Treatment with anti-TNF-
alpha agents must not be initiated in patients with 
active infection, malignancies, demyelinating diseas-
es of the central or peripheral nervous system, and 
congestive heart failure of NYHA classification grade 
III and IV (42). 
CONCLUSION
Treatment of childhood psoriasis is a challenge 
to dermatologists due to the lack of clinical trials 
and published data as well as insufficient guidelines 
to facilitate decision-making. Many medications are 
not registered for the use in the pediatric population 
or are used off-label. In recent years, development 
of biologic agents has led to a new era in psoriasis 
treatment. Considering the great impact of psoriasis 
on the quality of life of our young patients and their 
families, treatment is often a challenge and must be 
individualized, taking into consideration the efficacy 
and safety of the medication. Patient education and 
supportive care should be an important part of the 
treatment.
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